Kidney international · 2020
Transcription factor MafB in podocytes protects against the development of focal segmental glomerulosclerosis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Usui Toshiaki, Morito Naoki, Shawki Hossam H, Sato Yoshinori, Tsukaguchi Hiroyasu, Hamada Michito, Jeon Hyojung, Yadav Manoj Kumar, Kuno Akihiro, Tsunakawa Yuki, Okada Risa, Ojima Takaaki, Kanai Maho, Asano Keigo, Imamura Yuki, Koshida Ryusuke, Yoh Keigyou, Usui Joichi, Yokoi Hideki, Kasahara Masato, Yoshimura Ashio, Muratani Masafumi, Kudo Takashi, Oishi Hisashi, Yamagata Kunihiro, Takahashi Satoru
Аннотация
Focal segmental glomerulosclerosis (FSGS) is a common cause of steroid-resistant nephrotic syndrome. Spontaneous remission of FSGS is rare and steroid-resistant FSGS frequently progresses to renal failure. Many inheritable forms of FSGS have been described, caused by mutations in proteins that are important for podocyte function. Here, we show that a basic leucine zipper transcription factor, MafB, protects against FSGS. MAFB expression was found to be decreased in the podocytes of patients with FSGS. Moreover, conditional podocyte-specific MafB-knockout mice developed FSGS with massive proteinuria accompanied by depletion of the slit diaphragm-related proteins (Nphs1 and Magi2), and the podocyte-specific transcription factor Tcf21. These findings indicate that MafB plays a crucial role in the pathogenesis of FSGS. Consistent with this, adriamycin-induced FSGS and attendant proteinuria were ameliorated by MafB overexpression in the podocytes of MafB podocyte-specific transgenic mice. Thus, MafB could be a new therapeutic target for FSGS.